Supported by an educational grant from Novartis Pharmaceuticals Corporation
Despite multiple evidence-based expert guidelines for the management of chronic heart failure (HF)—as well as meaningful improvements in patient survival in recent years—clinicians remain challenged about how best to care for this complex population. Thus, significant gaps remain in clinicians’ adherence to treatment recommendations in HF, including underuse and/or inadequate dose titration of guideline-directed medical therapies (GDMTs).
Recent data from the CHAMP-HF (Change the Management of Patients With Heart Failure) registry show that among patients eligible for all classes of HF medication, only 1% simultaneously receive target doses of an angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), beta-blocker, and mineralocorticoid receptor antagonist (MRA).1
In this enduring myCME TOWN WALLTM presentation, the expert faculty will address some of the most vexing problems clinicians face in providing optimal medical therapy for patients with HF, including:
Best practices in risk assessment and stratification
Selecting medications based on pathophysiologic targets and comorbidities
Uptitrating indicated agents to evidence-based target doses
Leveraging the multidisciplinary care team to achieve optimal outcomes, especially during transitions in care
Reference 1. Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry. J Am Coll Cardiol. 2018;72:351-366.
This activity is designed for cardiologists, internists, and other clinicians who care for patients with chronic HF, including primary care physicians (ie, family medicine/general practice), nurse practitioners, and physician assistants.
At the conclusion of this activity, participants should be better able to:
Assess patients’ global clinical status, including prompt recognition of worsening HF
Apply evidence-based GDMT when managing patients with chronic HF, including uptitration of medication to recommended target levels
Identify candidates for newer HF agents (eg, sacubitril/valsartan, ivabradine)
Collaborate effectively with the multidisciplinary care team, including the patient and caregiver, especially during transitions in care
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, Haymarket Medical Education requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. Haymarket Medical Education resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
MODERATOR Peter Salgo, MD Professor of Medicine and Anesthesiology Columbia University College of Physicians and Surgeons Associate Director of Surgical Intensive Care Columbia University Medical Center New York, NY
Dr. Salgo has no relevant financial relationships to disclose.
FACULTY PRESENTERS Alison L. Bailey, MD, FACC, FAACVPR Program Director, Cardiovascular Diseases Fellowship Director, Preventive Cardiology and Cardiac Rehabilitation Program Erlanger Heart and Lung Institute University of Tennessee College of Medicine - Chattanooga Chattanooga, TN
Dr. Bailey was the lead investigator for clinical trials that received funding from Theracos, Inc., and ZOLL.
Peter S. Pang, MD, MS, FAHA, FACC, FACEP Associate Professor Department of Emergency Medicine Indiana University School of Medicine Indianapolis, IN
Dr. Pang receives consulting fees from Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, Roche Diagnostics, and Trevena and receives research grants from the American Heart Association, National Institutes of Health, Novartis Pharmaceuticals Corporation, Patient-Centered Outcomes Research Institute, and Roche Diagnostics.
Marc A. Silver, MD, FACP, FACC, FAHA, FHFSA Clinical Professor of Medicine University of Illinois at Chicago Chicago, IL
Dr. Silver has no relevant financial relationships to disclose.
ANCILLARY FACULTY PRESENTERS Ginger Biesbrock, PA-C, MPH, MPAS, AACC Vice President, MedAxiom Consulting Grand Rapids, MI
Ms. Biesbrock has no relevant financial relationships to disclose.
Robin E. Traufler, MN, APRN-BC, ACNP, CHFN Advanced Heart Health Center Palmetto Health Richland Columbia, SC
Ms. Traufler receives consulting fees from Abbott and is on the speaker’s bureau of ZOLL.
Accredited Provider Disclosures
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
Physician Assistant Continuing Education AAPA accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 Category 1 Credits for completing this activity.
Nurse Practitioner Continuing Education AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Novartis Pharmaceuticals Corporation or Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.